Skip to main content
Erschienen in: World Journal of Pediatrics 4/2019

10.05.2019 | Review Article

Progress in understanding youth-onset type 2 diabetes in the United States: recent lessons from clinical trials

verfasst von: Philip Zeitler

Erschienen in: World Journal of Pediatrics | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Due to the dramatic increase in the rates of childhood obesity and youth-onset type 2 diabetes (T2D) in the late 1990s in the United States, the US government, through the National Institute of Diabetes, Digestive Disease, and Kidney (NIDDK) and the Centers for Disease Control, funded a series of large studies and trials which, together, have formed the basis for much of what we currently understand about youth-onset T2D.

Data sources

The review focus on the recent results and implications of the treatment options for Type 2 Diabetes in Adolescents and Youth (TODAY) study and the Restoring Insulin Secretion (RISE) study.

Results and Conclusions

Both TODAY and RISE studies have provided critical insight into the unique aspects of the pathophysiology of youth-onset type 2 diabetes and also provided the evidence base for our current approach to the management of this disorder.
Literatur
2.
Zurück zum Zitat Hamman RF, Bell RA, Dabelea D, D'Agostino RB Jr, Dolan L, Imperatore G, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336–41.CrossRefPubMedPubMedCentral Hamman RF, Bell RA, Dabelea D, D'Agostino RB Jr, Dolan L, Imperatore G, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336–41.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat HEALTHY Study Group, Foster GD, Linder B, Baranowski T, Cooper DM, Goldberg L, et al. A school based intervention for diabetes risk reduction. N Engl J Med. 2010;363:443–53.CrossRef HEALTHY Study Group, Foster GD, Linder B, Baranowski T, Cooper DM, Goldberg L, et al. A school based intervention for diabetes risk reduction. N Engl J Med. 2010;363:443–53.CrossRef
4.
Zurück zum Zitat TODAY Study Group, Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74–87.CrossRef TODAY Study Group, Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74–87.CrossRef
5.
Zurück zum Zitat Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67.CrossRefPubMed Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67.CrossRefPubMed
6.
Zurück zum Zitat TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–2256.CrossRefPubMedCentral TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–2256.CrossRefPubMedCentral
7.
Zurück zum Zitat Katz LL, Anderson BJ, McKay SV, Izquierdo R, Casey TL, Higgins LA, et al. Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes. Diabetes Care. 2016;39:1956–62.CrossRefPubMedPubMedCentral Katz LL, Anderson BJ, McKay SV, Izquierdo R, Casey TL, Higgins LA, et al. Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes. Diabetes Care. 2016;39:1956–62.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gandica R, Zeitler P. Update on youth-onset type 2 diabetes: lessons learned from the treatment options for type 2 diabetes in adolescents and youth clinical trial. Adv Pediatr. 2016;63:195–209.CrossRefPubMedPubMedCentral Gandica R, Zeitler P. Update on youth-onset type 2 diabetes: lessons learned from the treatment options for type 2 diabetes in adolescents and youth clinical trial. Adv Pediatr. 2016;63:195–209.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013;36:1749–57.CrossRefPubMedCentral TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013;36:1749–57.CrossRefPubMedCentral
10.
Zurück zum Zitat Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016;39:1635–42.CrossRefPubMedPubMedCentral Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016;39:1635–42.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Zeitler P, Hirst K, Copeland KC, El Ghormli L, Levitt Katz L, Levitsky LL, et al. HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. Diabetes Care. 2015;38:2285–92.CrossRefPubMedPubMedCentral Zeitler P, Hirst K, Copeland KC, El Ghormli L, Levitt Katz L, Levitsky LL, et al. HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. Diabetes Care. 2015;38:2285–92.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Arslanian S, El Ghormli L, Kim JY, Bacha F, Chan C, Ismail HM, et al. The shape of the glucose response curve during an oral glucose tolerance test: forerunner of heightened glycemic failure rates and accelerated decline in β-cell function in TODAY. Diabetes Care. 2019;42:164-72.CrossRefPubMed Arslanian S, El Ghormli L, Kim JY, Bacha F, Chan C, Ismail HM, et al. The shape of the glucose response curve during an oral glucose tolerance test: forerunner of heightened glycemic failure rates and accelerated decline in β-cell function in TODAY. Diabetes Care. 2019;42:164-72.CrossRefPubMed
13.
Zurück zum Zitat TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758–64.CrossRefPubMedCentral TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758–64.CrossRefPubMedCentral
14.
Zurück zum Zitat TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013;36:1772–4.CrossRefPubMedCentral TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013;36:1772–4.CrossRefPubMedCentral
15.
Zurück zum Zitat Weinstock RS, Drews KL, Caprio S, Leibel NI, McKay SV, Zeitler PS, et al. Metabolic syndrome is common and persistent in youth-onset type 2 diabetes: results from the TODAY clinical trial. Obesity. 2015;23:1357–61.CrossRefPubMed Weinstock RS, Drews KL, Caprio S, Leibel NI, McKay SV, Zeitler PS, et al. Metabolic syndrome is common and persistent in youth-onset type 2 diabetes: results from the TODAY clinical trial. Obesity. 2015;23:1357–61.CrossRefPubMed
16.
Zurück zum Zitat TODAY Study Group. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatr Diabetes. 2015;16:39–47.CrossRef TODAY Study Group. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatr Diabetes. 2015;16:39–47.CrossRef
17.
Zurück zum Zitat Bacha F, Gidding SS, Pyle L, Levitt Katz L, Kriska A, Nadeau KJ, et al. Relationship of cardiac structure and function to cardiorespiratory fitness and lean body mass in adolescents. J Pediatr. 2016;177:159–66.CrossRefPubMedPubMedCentral Bacha F, Gidding SS, Pyle L, Levitt Katz L, Kriska A, Nadeau KJ, et al. Relationship of cardiac structure and function to cardiorespiratory fitness and lean body mass in adolescents. J Pediatr. 2016;177:159–66.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, et al. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009;94:3687–95.CrossRefPubMedPubMedCentral Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, et al. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009;94:3687–95.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Shah AS, El Ghormli L, Gidding SS, Bacha F, Nadeau KJ, Levitt Katz LE, et al. Prevalence of arterial stiffness in adolescents with type 2 diabetes in the TODAY cohort: Relationships to glycemic control and other risk factors. J Diabetes Complicat. 2018;32:740–45.CrossRef Shah AS, El Ghormli L, Gidding SS, Bacha F, Nadeau KJ, Levitt Katz LE, et al. Prevalence of arterial stiffness in adolescents with type 2 diabetes in the TODAY cohort: Relationships to glycemic control and other risk factors. J Diabetes Complicat. 2018;32:740–45.CrossRef
20.
Zurück zum Zitat Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67:7–8.CrossRef Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67:7–8.CrossRef
21.
Zurück zum Zitat Bjornstad P, Cherney DZ, Maahs DM, Nadeau KJ. Diabetic kidney disease in adolescents with type 2 diabetes: new insights and potential therapies. Curr Diab Rep. 2016;16:11.CrossRefPubMedPubMedCentral Bjornstad P, Cherney DZ, Maahs DM, Nadeau KJ. Diabetic kidney disease in adolescents with type 2 diabetes: new insights and potential therapies. Curr Diab Rep. 2016;16:11.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bjornstad P, Nehus E, El Ghormli L, Bacha F, Libman IM, McKay S, et al. Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. Am J Kidney Dis. 2018;71:65–74.CrossRefPubMed Bjornstad P, Nehus E, El Ghormli L, Bacha F, Libman IM, McKay S, et al. Insulin sensitivity and diabetic kidney disease in children and adolescents with type 2 diabetes: an observational analysis of data from the TODAY clinical trial. Am J Kidney Dis. 2018;71:65–74.CrossRefPubMed
23.
Zurück zum Zitat TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY Clinical Trial. Diabetes Care. 2013;36:1735–41.CrossRefPubMedCentral TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY Clinical Trial. Diabetes Care. 2013;36:1735–41.CrossRefPubMedCentral
24.
Zurück zum Zitat Bjornstad P, Maahs DM, Cherney DZ, Cree-Green M, West A, Pyle L, et al. Insulin sensitivity is an important determinant of renal health in adolescents with type 2 diabetes. Diabetes Care. 2014;37:3033–9.CrossRefPubMedPubMedCentral Bjornstad P, Maahs DM, Cherney DZ, Cree-Green M, West A, Pyle L, et al. Insulin sensitivity is an important determinant of renal health in adolescents with type 2 diabetes. Diabetes Care. 2014;37:3033–9.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Inge TH, Laffel LM, Jenkins TM, Marcus MD, Leibel NI, Brandt ML, et al. Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. JAMA Pediatr. 2018;172:452–60.CrossRefPubMedPubMedCentral Inge TH, Laffel LM, Jenkins TM, Marcus MD, Leibel NI, Brandt ML, et al. Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents. JAMA Pediatr. 2018;172:452–60.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–8.CrossRefPubMedPubMedCentral Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–8.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat RISE Consortium. Restoring insulin secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37:780–8.CrossRef RISE Consortium. Restoring insulin secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37:780–8.CrossRef
28.
Zurück zum Zitat RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I Observations using the hyperglycemic clamp. Diabetes Care. 2018;41:1696–706.CrossRef RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I Observations using the hyperglycemic clamp. Diabetes Care. 2018;41:1696–706.CrossRef
29.
Zurück zum Zitat Rise Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II Observations using the oral glucose tolerance test. Diabetes Care. 2018;41:1707–16.CrossRef Rise Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II Observations using the oral glucose tolerance test. Diabetes Care. 2018;41:1707–16.CrossRef
30.
Zurück zum Zitat Rise Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018;41:1717–25.CrossRef Rise Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018;41:1717–25.CrossRef
31.
Zurück zum Zitat Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and ß-cell dysfunction. Endocr Rev. 2008;29:351–66.CrossRefPubMed Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and ß-cell dysfunction. Endocr Rev. 2008;29:351–66.CrossRefPubMed
32.
Zurück zum Zitat The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–14.CrossRef The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–14.CrossRef
33.
Zurück zum Zitat The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef
34.
Zurück zum Zitat Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–60.CrossRefPubMed Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–60.CrossRefPubMed
35.
Zurück zum Zitat Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41:2648–68.CrossRefPubMedPubMedCentral Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41:2648–68.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, Reinehr T, Tandon N, et al. Type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19(suppl 27):28–46.CrossRefPubMed Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, Reinehr T, Tandon N, et al. Type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19(suppl 27):28–46.CrossRefPubMed
Metadaten
Titel
Progress in understanding youth-onset type 2 diabetes in the United States: recent lessons from clinical trials
verfasst von
Philip Zeitler
Publikationsdatum
10.05.2019
Verlag
Springer Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 4/2019
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-019-00247-1

Weitere Artikel der Ausgabe 4/2019

World Journal of Pediatrics 4/2019 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.